^
Association details:
| Biomarker: | FGFR1-TACC1 fusion |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Published date:
09/22/2021
Excerpt:
Among patients with CCA who received futibatinib 20 mg QD (n = 64)...The responders included 1 patient with extrahepatic CCA harboring an FGFR2-POC1B fusion (mDOR, 3.5 months)...FGFR2 p.C383R mutation (n = 1), or an FGFR2 p.W290C mutation (n = 1; Supplementary Table S2)....PRs were seen in 2 of 9 patients, 1 with an FGFR2 amplification (DOR, 3.5 months) and the other with an FGFR3–TACC3 fusion (DOR, 5.4 months)....The PFS of the patients with the FGFR2 p.C383R and p.W290C mutations were 9.2 and 8.9 months, respectively.
DOI:
10.1158/2159-8290.CD-21-0697
Trial ID:
